Talphera (NASDAQ:TLPH) Stock Price Crosses Below 200-Day Moving Average – Here’s What Happened

Posted by Jessica Moore on Nov 14th, 2026

Talphera, Inc. (NASDAQ:TLPH – Get Free Report) shares crossed below its two hundred day moving average during trading on Friday. The stock has a two hundred day moving average of $1.01 and traded as low as $0.77. Talphera shares last traded at $0.9060, with a volume of 1,219,659 shares traded.

Analysts Set New Price Targets

TLPH has been the topic of a number of recent analyst reports. Wall Street Zen upgraded shares of Talphera to a “hold” rating in a report on Saturday, August 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Talphera in a research report on Thursday, October 15th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $3.00 price objective on shares of Talphera in a research note on Thursday, August 13th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $3.00.

Check Out Our Latest Report on TLPH

Talphera Trading Down 12.5%

The firm’s fifty day moving average price is $1.11 and its 200 day moving average price is $1.01. The firm has a market capitalization of $47.03 million, a PE ratio of -4.31 and a beta of 0.77.

Talphera (NASDAQ:TLPH – Get Free Report) last posted its quarterly earnings results on Thursday, November 12th. The company reported ($0.05) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.05). As a group, research analysts expect that Talphera, Inc. will post -0.23 EPS for the current year.

Talphera Company Profile

(Get Free Report)

Talphera, Inc., formerly known as AcelRx Pharmaceuticals, is a specialty pharmaceutical company focused on developing and commercializing treatments for acute pain and critical care. The company’s portfolio includes DSUVIA, a sublingual formulation of sufentanil for the management of acute pain in adults in medically supervised settings. Talphera is also developing Niyad, a nafamostat-based anticoagulant intended for use in extracorporeal circuits during continuous renal replacement therapy. The company’s work in this area is aimed at addressing treatment needs in critical care settings.